Patents by Inventor Masahiro FUKASAKA
Masahiro FUKASAKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200376111Abstract: A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.Type: ApplicationFiled: August 18, 2020Publication date: December 3, 2020Applicant: NITTO DENKO CORPORATIONInventors: Masahiro FUKASAKA, Arimichi OKAZAKI, Daisuke ASARI, Mitsuhiko HORI, Shizuo AKIRA, Osamu TAKEUCHI
-
Patent number: 10744197Abstract: The present invention provides a vaccine pharmaceutical composition for oral administration that enables stable storage of an influenza virus antigen and a method for producing the pharmaceutical composition. Provided is a vaccine pharmaceutical composition for oral administration containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.Type: GrantFiled: November 28, 2016Date of Patent: August 18, 2020Assignee: NITTO DENKO CORPORATIONInventors: Takuya Shishido, Daisuke Asari, Eiji Kiyotoh, Kyohei Matsushita, Wenjing Li, Masahiro Fukasaka, Katsuyuki Okubo, Mitsuhiko Hori
-
Patent number: 10722570Abstract: The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine can be stably maintained even if the preparation is stored without strict temperature control and which can be stably supplied. The present invention also provides a method for producing the dried influenza vaccine preparation. Provided is a dried influenza vaccine preparation including: an influenza vaccine antigen; a disaccharide; and an amino acid.Type: GrantFiled: November 28, 2016Date of Patent: July 28, 2020Assignee: NITTO DENKO CORPORATIONInventors: Eiji Kiyotoh, Mitsuhiko Hori, Daisuke Asari, Katsuyuki Okubo, Takuya Shishido, Masahiro Fukasaka, Kyohei Matsushita
-
Patent number: 10688120Abstract: The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease.Type: GrantFiled: April 28, 2016Date of Patent: June 23, 2020Assignee: NITTO DENKO CORPORATIONInventors: Kyohei Matsushita, Masahiro Fukasaka, Takuya Shishido, Daisuke Asari, Katsuyuki Okubo, Mitsuhiko Hori
-
Patent number: 10391167Abstract: The present disclosure relates to a method for inducing humoral immunity in a human or animal, that includes administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane. The mucosal vaccine composition includes at least one antigen derived from a pathogen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Pantoea, Acetobacter, Zymomonas, and Xanthomonas, or a salt of the lipopolysaccharide, wherein the mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500.Type: GrantFiled: October 2, 2014Date of Patent: August 27, 2019Assignee: NITTO DENKO CORPORATIONInventors: Masahiro Fukasaka, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Eiji Kiyotoh, Kyohei Matsushita
-
Publication number: 20180326041Abstract: The present invention provides a vaccine pharmaceutical composition for oral administration that enables stable storage of an influenza virus antigen and a method for producing the pharmaceutical composition. Provided is a vaccine pharmaceutical composition for oral administration containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.Type: ApplicationFiled: November 28, 2016Publication date: November 15, 2018Applicant: NITTO DENKO CORPORATIONInventors: Takuya SHISHIDO, Daisuke ASARI, Eiji KIYOTOH, Kyohei MATSUSHITA, Wenjing LI, Masahiro FUKASAKA, Katsuyuki OKUBO, Mitsuhiko HORI
-
Publication number: 20180326042Abstract: The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine can be stably maintained even if the preparation is stored without strict temperature control and which can be stably supplied. The present invention also provides a method for producing the dried influenza vaccine preparation. Provided is a dried influenza vaccine preparation including: an influenza vaccine antigen; a disaccharide; and an-amino acid.Type: ApplicationFiled: November 28, 2016Publication date: November 15, 2018Applicant: NITTO DENKO CORPORATIONInventors: Eiji KIYOTOH, Mitsuhiko HORI, Daisuke ASARI, Katsuyuki OKUBO, Takuya SHISHIDO, Masahiro FUKASAKA, Kyohei MATSUSHITA
-
Patent number: 10092642Abstract: The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response.Type: GrantFiled: October 2, 2014Date of Patent: October 9, 2018Assignee: NITTO DENKO CORPORATIONInventors: Masahiro Fukasaka, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Eiji Kiyotoh, Kyohei Matsushita
-
Patent number: 10071155Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively.Type: GrantFiled: October 2, 2014Date of Patent: September 11, 2018Assignee: NITTO DENKO CORPORATIONInventors: Eiji Kiyotoh, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Masahiro Fukasaka, Kyohei Matsushita
-
Publication number: 20180147235Abstract: The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease.Type: ApplicationFiled: April 28, 2016Publication date: May 31, 2018Applicant: NITTO DENKO CORPORATIONInventors: Kyohei MATSUSHITA, Masahiro FUKASAKA, Takuya SHISHIDO, Daisuke ASARI, Katsuyuki OKUBO, Mitsuhiko HORI
-
Patent number: 9962439Abstract: The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively.Type: GrantFiled: October 2, 2014Date of Patent: May 8, 2018Assignee: NITTO DENKO CORPORATIONInventors: Kyohei Matsushita, Masahiro Fukasaka, Arimichi Okazaki, Eiji Kiyotoh, Katsuyuki Okubo, Daisuke Asari, Mitsuhiko Hori
-
Publication number: 20170028054Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.Type: ApplicationFiled: October 11, 2016Publication date: February 2, 2017Applicant: NITTO DENKO CORPORATIONInventors: Masahiro FUKASAKA, Arimichi OKAZAKI, Daisuke ASARI, Mitsuhiko HORI, Shizuo AKIRA, Osamu TAKEUCHI
-
Patent number: 9498527Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.Type: GrantFiled: April 3, 2013Date of Patent: November 22, 2016Assignee: NITTO DENKO CORPORATIONInventors: Masahiro Fukasaka, Arimichi Okazaki, Daisuke Asari, Mitsuhiko Hori, Shizuo Akira, Osamu Takeuchi
-
Publication number: 20160287697Abstract: The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively.Type: ApplicationFiled: October 2, 2014Publication date: October 6, 2016Applicant: NITTO DENKO CORPORATIONInventors: Kyohei MATSUSHITA, Masahiro FUKASAKA, Arimichi OKAZAKI, Eiji KIYOTOH, Katsuyuki OKUBO, Daisuke ASARI, Mitsuhiko HORI
-
Publication number: 20160228540Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively.Type: ApplicationFiled: October 2, 2014Publication date: August 11, 2016Applicant: NITTO DENKO CORPORATIONInventors: Eiji KIYOTOH, Mitsuhiko HORI, Katsuyuki OKUBO, Daisuke ASARI, Arimichi OKAZAKI, Masahiro FUKASAKA, Kyohei MATSUSHITA
-
Publication number: 20160213773Abstract: The present invention aims at providing a vaccine composition capable of being administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is safe, useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and capable of effectively inducing the systemic immune response and mucosal immune response.Type: ApplicationFiled: October 2, 2014Publication date: July 28, 2016Applicant: NITTO DENKO CORPORATIONInventors: Masahiro FUKASAKA, Mitsuhiko HORI, Katsuyuki OKUBO, Daisuke ASARI, Arimichi OKAZAKI, Eiji KIYOTOH, Kyohei MATSUSHITA
-
Publication number: 20160206728Abstract: The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine antigen can be stably maintained even when stored without strictly maintaining a low temperature, and which can be stably supplied. The present invention also provides a method of producing the dried influenza vaccine preparation. The present invention provides a dried influenza vaccine preparation containing an influenza vaccine antigen and a disaccharide, wherein the disaccharide is at least one selected from the group consisting of sucrose, maltose, palatinose, melibiose, isomalt, cellobiose, allolactose, isomaltose, sophorose, lactobionic acid, laminaribiose, xylobiose, turanose, gentiobiose, rutinose, kojibiose, nigerose, robinose, neohesperidose, sucralose, and maltitol.Type: ApplicationFiled: October 2, 2014Publication date: July 21, 2016Applicant: NITTO DENKO CORPORATIONInventors: Eiji KIYOTOH, Mitsuhiko HORI, Daisuke ASARI, Arimichi OKAZAKI, Masahiro FUKASAKA
-
Publication number: 20160193327Abstract: The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response.Type: ApplicationFiled: October 2, 2014Publication date: July 7, 2016Applicant: NITTO DENKO CORPORATIONInventors: Masahiro FUKASAKA, Mitsuhiko HORI, Katsuyuki OKUBO, Daisuke ASARI, Arimichi OKAZAKI, Eiji KIYOTOH, Kyohei MATSUSHITA
-
Publication number: 20130266612Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.Type: ApplicationFiled: April 3, 2013Publication date: October 10, 2013Applicants: OSAKA UNIVERSITY, NITTO DENKO CORPORATIONInventors: Masahiro FUKASAKA, Arimichi OKAZAKI, Daisuke ASARI, Mitsuhiko HORI, Shizuo AKIRA, Osamu TAKEUCHI